درباره این اپیزود
Recently, the U.S. Patent and Trademark Office’s released a dataset that contained over 250,000 records, included patent applications and granted patents; the USPTO was interested in the insights this data could reveal to guide cancer research. Di Cross, Director of Research at Clarivate Analytics, talks about her team’s recent award winning submission to the USPTO’s challenge around data analysis and visualization for the Cancer Moonshot Initiative. Listen as she talks about the Cancer Innovation VU tool and how it is a means for others to explore and interact with data to help accelerate the development of cancer treatment.
انگلیسی
انگلستان
در این اپیزود
رونوشت 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
جستجوی اپیزودهای گذشته
اپیزودهای قبلی Oncology Talks را جستجو کن.
قسمت های دیگر در این پادکست
The recent buzz around CRISPR-Cas9, a genome editing tool, has revolved around its potential for treating various genetic diseases, including cancer. Jack Hopwood, Intellectual Property Consultant and Bertrand Sautier, Strategic Account Manager at Clarivate Analytics talk about how research activit…
Cancer immunotherapy research continues to evolve and offers patients a transformative alternative to traditional therapies. Anette Briendl, Senior Science Editor at BioWorld, talks about the current research landscape for immunotherapies. Learn about the challenges and potential of emerging therap…
Join Chris Willis, Manager of Discovery and Translational Sciences at Clarivate Analytics, as he talks about immuno-oncology, why it is promising for cancer patients and how it continues to evolve. Learn more about the new approved drugs on the market that treat indications of cancer and the way in…
Immuno-oncology therapies have opened up the most promising frontiers in cancer treatment today. But, with drug development costs increasing, how is it possible to maintain commercial viability?
Peter Winter, Editor at BioWorld, talks about challenges to commercial viability in the immuno-oncolog…
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به Clarivate Analytics – Formerly the IP&Science business of Thomson Reuters است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم
